Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee
Daxor (NASDAQ: DXR), a leader in blood volume measurement technology, has been awarded a $300,000 SBIR matching fund by Launch Tennessee (LaunchTN). This funding will support the development of Daxor's next-generation point-of-care blood volume analyzer, building on their Phase II award from the Defense Health Agency. The award underscores Daxor's commitment to innovation, job creation, and its presence in Oak Ridge, Tennessee.
CEO Michael Feldschuh highlighted the importance of this non-dilutive funding in empowering clinicians with advanced tools for optimal fluid management and enhancing patient outcomes. LaunchTN, a public-private partnership, aims to foster entrepreneurship and economic development in Tennessee through various support mechanisms.
Daxor (NASDAQ: DXR), leader nella tecnologia di misurazione del volume sanguigno, ha ricevuto un contributo corrispondente di $300,000 SBIR da Launch Tennessee (LaunchTN). Questo finanziamento supporterà lo sviluppo del prossimo analizzatore di volume sanguigno point-of-care di Daxor, basandosi sul loro premio della Fase II dall'Agenzia della Salute della Difesa. Il premio sottolinea l'impegno di Daxor per l'innovazione, la creazione di posti di lavoro e la sua presenza a Oak Ridge, Tennessee.
Il CEO Michael Feldschuh ha evidenziato l'importanza di questo finanziamento non diluitivo nell'empowerare i medici con strumenti avanzati per una gestione ottimale dei fluidi e nel migliorare i risultati per i pazienti. LaunchTN, una partnership pubblico-privata, mira a promuovere l'imprenditorialità e lo sviluppo economico in Tennessee attraverso vari meccanismi di supporto.
Daxor (NASDAQ: DXR), líder en tecnología de medición del volumen sanguíneo, ha sido galardonado con un fondo correspondiente de $300,000 SBIR por Launch Tennessee (LaunchTN). Este financiamiento apoyará el desarrollo del analizador de volumen sanguíneo de próxima generación de Daxor, basándose en su premio de Fase II de la Agencia de Salud de Defensa. El premio subraya el compromiso de Daxor con la innovación, la creación de empleos y su presencia en Oak Ridge, Tennessee.
El CEO Michael Feldschuh destacó la importancia de este financiamiento no dilutivo para empoderar a los clínicos con herramientas avanzadas para una gestión óptima de fluidos y mejorar los resultados de los pacientes. LaunchTN, una asociación pública-privada, tiene como objetivo fomentar el emprendimiento y el desarrollo económico en Tennessee a través de varios mecanismos de apoyo.
Daxor (NASDAQ: DXR), 혈액량 측정 기술의 선두주자로, Launch Tennessee (LaunchTN)로부터 30만 달러의 SBIR 매칭 펀드를 수상했습니다. 이 자금은 Daxor의 차세대 포인트 오브 케어 혈액량 분석기 개발을 지원할 것이며, 방위 건강 청의 2단계 수상에 기반합니다. 이 상은 Daxor의 혁신, 일자리 창출 및 테네시주 오크 리지에 대한 존재 의지를 강조합니다.
CEO 마이클 펠드슈는 이 비희석 자금이 임상의에게 최적의 체액 관리를 위한 고급 도구를 제공하고 환자 결과를 향상시키는 중요성을 강조했습니다. LaunchTN은 테네시의 기업가 정신과 경제 개발을 촉진하기 위한 공공-민간 파트너십으로, 다양한 지원 메커니즘을 통해 이 목표를 달성하고자 합니다.
Daxor (NASDAQ: DXR), leader dans la technologie de mesure du volume sanguin, a reçu un financement de correspondance de 300 000 $ SBIR de Launch Tennessee (LaunchTN). Ce financement soutiendra le développement du prochain analyseur de volume sanguin point-of-care de Daxor, tirant parti de leur prix de Phase II de l'Agence de la santé de la défense. Ce prix souligne l'engagement de Daxor envers l'innovation, la création d'emplois et sa présence à Oak Ridge, Tennessee.
Le PDG Michael Feldschuh a souligné l'importance de ce financement non dilutif pour donner aux cliniciens des outils avancés pour une gestion optimale des fluides et améliorer les résultats pour les patients. LaunchTN, un partenariat public-privé, vise à favoriser l'entrepreneuriat et le développement économique au Tennessee à travers divers mécanismes de soutien.
Daxor (NASDAQ: DXR), führend in der Technologie zur Messung des Blutvolumens, hat von Launch Tennessee (LaunchTN) einen SBIR-Matching-Fonds über 300.000 US-Dollar erhalten. Diese Finanzierung wird die Entwicklung von Daxors nächster Generation von Blutvolumenanalysatoren am Point-of-Care unterstützen und basiert auf ihrem Phase-II-Award von der Defense Health Agency. Die Auszeichnung unterstreicht Daxors Engagement für Innovation, die Schaffung von Arbeitsplätzen und ihre Präsenz in Oak Ridge, Tennessee.
CEO Michael Feldschuh hob die Bedeutung dieser nicht verwässernden Finanzierung hervor, um Klinikern fortschrittliche Werkzeuge für ein optimales Flüssigkeitsmanagement anzubieten und die Patientenergebnisse zu verbessern. LaunchTN, eine öffentlich-private Partnerschaft, hat das Ziel, Unternehmertum und wirtschaftliche Entwicklung in Tennessee durch verschiedene Unterstützungsmechanismen zu fördern.
- Received $300,000 SBIR matching fund award from Launch Tennessee
- Funding supports development of next-generation blood volume analyzer
- Builds on existing Phase II award from Defense Health Agency
- Reinforces company's commitment to innovation and job creation in Tennessee
- None.
The SBIR Matching Fund Award Will Drive Our Innovation, Commercialization Efforts, and Job Creation
Oak Ridge, TN, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces Launch Tennessee (LaunchTN) awarded Daxor Corporation a
“This award is a welcome addition to Daxor’s long-standing and robust portfolio of non-dilutive funding, which focuses on leveraging public funding to empower clinicians with advanced tools for optimal fluid management to enhance patient outcomes,” said Michael Feldschuh, CEO and President of Daxor. “This award highlights our unwavering commitment to innovation, job creation, and our enduring presence in Oak Ridge. We are proud to be part of the vibrant Tennessee community and grateful for this recognition.”
LaunchTN is a public-private partnership that supports entrepreneurship and economic development with a goal to make Tennessee the best state in the country for startups. The organization fosters entrepreneurship, technology advancement and workforce development through capital access, commercialization, mentorship, marketing and partnerships. This award serves as a testament to Daxor’s commitment to the growth of its Tennessee-based operations. Learn more HERE.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100™ (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What is the amount of the SBIR matching fund award Daxor (DXR) received?
What will Daxor (DXR) use the Launch Tennessee award for?
How does the Launch Tennessee award benefit Daxor 's (DXR) operations in Tennessee?
What is Launch Tennessee's role in supporting companies like Daxor (DXR)?
